Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress-MedSci.cn

Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress

Paik, P; Sakai, H; Bruns, R; Scheele, J; Straub, J; Felip, E

ANNALS OF ONCOLOGY, 2018; 29 ():

科室
- - 订阅+
  - 更多科室
工具
服务